Investor Relations

About
Pipeline
- Overview
- SNS-301
- SNS-401
- Vista
- Presentations
Platform
Our Leadership
Careers
Investors and Media

Contact

Investor Relations

About
Pipeline
- Overview
- SNS-301
- SNS-401
- Vista
- Presentations
Platform
Our Leadership
Careers
Investors and Media

Contact Us

Investor Contact:

Julie Seidel | Courtney Turiano
Stern Investor Relations, Inc.
ir@senseibio.com

Name

Email

Subject

Comments

Leave this field blank

Investor Tools

Email Alerts
Investor FAQs
RSS Feeds
Contact Us

About

We are a clinical-stage immunotherapy company engaged in the discovery and development of next generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

Contact

Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850

Phone No

+1.240.243.8000

Boston R&D Location
Smart Labs, Seaport District
6 Tide Street
Boston, MA 02210

Email

info@senseibio.com

Legal

Privacy Policy

Social Links

Go to Top